Exploration of Targeted Anti-tumor Therapy

CM conditions	Adipocytes	Matrigel-based ECM	Media type
1	–	–	DMEM/FBS
2	–	+	DMEM/FBS
3	–	–	Supplemented MEGM
4	–	–	Supplemented MEGM
5	+	–	DMEM/FBS
6	+	+	DMEM/FBS
7	+	–	Supplemented MEGM
8	+	+	Supplemented MEGM

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/1002201_sup_1.pdf.

Declarations

Acknowledgments

We would like to thank Andrada Tarta (Department of Biomedical Sciences, University of Guelph), for her valuable contribution to the optimization of the adipocyte differentiation protocol at the A.V.P lab.

Author contributions

CMVS: Conceptualization, Investigation, Formal analysis, Validation, Visualization, Writing—original draft, Writing—review & editing. GK: Conceptualization, Investigation, Formal analysis, Writing—review & editing. NKP, EE and AVVC: Investigation, Formal analysis. SLC and AMVP: Conceptualization, Methodology, Writing—review & editing, Supervision, Project administration, Funding acquisition. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The data are available from the authors upon request (sherri.christian@mun.ca; aviloria@uoguelph.ca).

Funding

This work was funded by a Cancer Research Society operating grant to SC and AVP [22130]; an Internal Faculty of Science, Memorial University of Newfoundland award to SC; a Natural Sciences and Engineering Research Council (NSERC) of Canada grant to AVP [#401248]; CMVS was supported by an Art Rouse Memorial Master of Science scholarship from the Ontario Veterinary College (OVC); GK was supported by a Carol Ann Cole Comfort Heart Summer Studentship via the Beatrice Hunter Cancer Research Institute and is supported by a CGS-M award from the Canadian Institutes of Health Research (CIHR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2015;293:247–69. [DOI] [PubMed]

Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627–35. [DOI] [PubMed]

Jiralerspong S, Goodwin PJ. Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol. 2016;34:4203–16. [DOI] [PubMed]

Blair CK, Wiggins CL, Nibbe AM, Storlie CB, Prossnitz ER, Royce M, et al. Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics. NPJ Breast Cancer. 2019;5:33. [DOI] [PubMed] [PMC]

Haakinson DJ, Leeds SG, Dueck AC, Gray RJ, Wasif N, Stucky CC, et al. The impact of obesity on breast cancer: a retrospective review. Ann Surg Oncol. 2012;19;3012–8. [DOI] [PubMed]

Lee K, Kruper L, Dieli-Conwright CM, Mortimer JE. The impact of obesity on breast cancer diagnosis and treatment. Curr Oncol Rep. 2019;21:41. [DOI] [PubMed] [PMC]

Jeffery E, Wing A, Holtrup B, Sebo Z, Kaplan JL, Saavedra-Peña R, et al. The adipose tissue microenvironment regulates depot-specific adipogenesis in obesity. Cell Metab. 2016;24:142–50. [DOI] [PubMed] [PMC]

Craft CS, Scheller EL. Evolution of the marrow adipose tissue microenvironment. Calcif Tissue Int. 2017;100:461–75. [DOI] [PubMed] [PMC]

Horowitz MC, Berry R, Holtrup B, Sebo Z, Nelson T, Fretz JA, et al. Bone marrow adipocytes. Adipocyte. 2017;6:193–204. [DOI] [PubMed] [PMC]

10.

Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, et al. Distant metastasis in triple-negative breast cancer. Neoplasma. 2013;60:290–4. [DOI] [PubMed]

11.

Evangelista GCM, Salvador PA, Soares SMA, Barros LRC, Xavier FHDC, Abdo LM, et al. 4T1 mammary carcinoma colonization of metastatic niches is accelerated by obesity. Front Oncol. 2019;9:685. [DOI] [PubMed] [PMC]

12.

Templeton ZS, Lie WR, Wang W, Rosenberg-Hasson Y, Alluri RV, Tamaresis JS, et al. Breast cancer cell colonization of the human bone marrow adipose tissue niche. Neoplasia. 2015;17:849–61. [DOI] [PubMed] [PMC]

13.

Soni S, Torvund M, Mandal CC. Molecular insights into the interplay between adiposity, breast cancer and bone metastasis. Clin Exp Metastasis. 2021;38:119–38. [DOI] [PubMed]

14.

Yang J, Bahcecioglu G, Zorlutuna P. The extracellular matrix and vesicles modulate the breast tumor microenvironment. Bioengineering (Basel). 2020;7:124. [DOI] [PubMed] [PMC]

15.

Zhao C, Wu M, Zeng N, Xiong M, Hu W, Lv W, et al. Cancer-associated adipocytes: emerging supporters in breast cancer. J Exp Clin Cancer Res. 2020;39:156. [DOI] [PubMed] [PMC]

16.

Goddard ET, Bozic I, Riddell SR, Ghajar CM. Dormant tumour cells, their niches and the influence of immunity. Nat Cell Biol. 2018;20:1240–9. [DOI] [PubMed]

17.

Kai FB, Laklai H, Weaver VM. Force matters: biomechanical regulation of cell invasion and migration in disease. Trends Cell Biol. 2016;26:486–97. [DOI] [PubMed] [PMC]

18.

Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem. 2007;101:805–15. [DOI] [PubMed]

19.

Arneth B. Tumor microenvironment. Medicina. 2019;56:15. [DOI] [PubMed] [PMC]

20.

Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166:21–45. [DOI] [PubMed]

21.

Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35:645–54. [DOI] [PubMed]

22.

Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117–34. [DOI] [PubMed] [PMC]

23.

Pallegar NK, Garland CJ, Mahendralingam M, Viloria-Petit AM, Christian SL. A novel 3-dimensional co-culture method reveals a partial mesenchymal to epithelial transition in breast cancer cells induced by adipocytes. J Mammary Gland Biol Neoplasia. 2018;24:85–97. [DOI] [PubMed]

24.

Bidarra SJ, Oliveira P, Rocha S, Saraiva DP, Oliveira C, Barrias CC. A 3D in vitro model to explore the inter-conversion between epithelial and mesenchymal states during EMT and its reversion. Sci Rep. 2016;6:27072. [DOI] [PubMed] [PMC]

25.

Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat. 1994;31:325–35. [DOI] [PubMed]

26.

Asante EC, Pallegar NK, Hoffmann AJ, Viloria-Petit AM, Christian SL. Adipose tissue from lean and obese mice induces a mesenchymal to epithelial transition-like effect in triple negative breast cancers cells grown in 3-dimensional culture. Int J Mol Sci. 2020;21:6439. [DOI] [PubMed] [PMC]

27.

Sinha D, Saha P, Samanta A, Bishayee A. Emerging concepts of hybrid epithelial-to-mesenchymal transition in cancer progression. Biomolecules. 2020;10:1561. [DOI] [PubMed] [PMC]

28.

Bowers LW, Rossi EL, McDonell SB, Doerstling SS, Khatib SA, Lineberger CG, et al. Leptin signaling mediates obesity-associated CSC enrichment and EMT in preclinical TNBC models. Mol Cancer Res. 2018;16:869–79. [DOI] [PubMed] [PMC]

29.

Lee YK, Jung WH, Koo JS. Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells. Breast Cancer Res Treat. 2015;153:323–35. [DOI] [PubMed]

30.

Kim SM, Lim EJ, Yoo KC, Zhao Y, Kang JH, Lim EJ, et al. Glioblastoma-educated mesenchymal stem-like cells promote glioblastoma infiltration via extracellular matrix remodelling in the tumour microenvironment. Clin Transl Med. 2022;12:e997. [DOI] [PubMed] [PMC]

31.

Liu NQ, Stingl C, Look MP, Smid M, Braakman RB, De Marchi T, et al. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. J Natl Cancer Inst. 2014;106:djt376. [DOI] [PubMed] [PMC]

32.

Tang W, Zhou M, Dorsey TH, Prieto DA, Wang XW, Ruppin E, et al. Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival. Genome Med. 2018;10:94. [DOI] [PubMed] [PMC]

33.

Lánczky A, Győrffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021;23:e27633. [DOI] [PubMed] [PMC]

34.

Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res. 2001;29:e45. [DOI] [PubMed] [PMC]

35.

Hughes CS, Postovit LM, Lajoie GA. Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics. 2010;10:1886–90. [DOI] [PubMed]

36.

Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat. 2010;122:35–43. [DOI] [PubMed] [PMC]

37.

Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE, et al. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nat Commun. 2020;11:2416. [DOI] [PubMed] [PMC]

38.

Yang N, Cao DF, Yin XX, Zhou HH, Mao XY. Lysyl oxidases: emerging biomarkers and therapeutic targets for various diseases. Biomed Pharmaco. 2020;131:110791. [DOI] [PubMed]

39.

Pastel E, Price E, Sjöholm K, McCulloch LJ, Rittig N, Liversedge N, et al. Lysyl oxidase and adipose tissue dysfunction. Metabolism. 2018;78:118–27. [DOI] [PubMed]

40.

Miana M, Galán M, Martínez-Martínez E, Varona S, Jurado-López R, Bausa-Miranda B, et al. The lysyl oxidase inhibitor β-aminopropionitrile reduces body weight gain and improves the metabolic profile in diet-induced obesity in rats. Dis Model Mech. 2015;8:543–51. [DOI] [PubMed] [PMC]

41.

Bondareva A, Downey CM, Ayres F, Liu W, Boyd SK, Hallgrimsson B, et al. The lysyl oxidase inhibitor, β-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells. PLoS One. 2009;4:e5620. [DOI] [PubMed] [PMC]

42.

Griner JD, Rogers CJ, Zhu MJ, Du M. Lysyl oxidase propeptide promotes adipogenesis through inhibition of FGF-2 signaling. Adipocyte. 2017;6:12–9. [DOI] [PubMed] [PMC]

43.

Josan C, Kakar S, Raha S. Matrigel® enhances 3T3-L1 cell differentiation. Adipocyte. 2021;10:361–77. [DOI] [PubMed] [PMC]

44.

Gao Y, Ma K, Kang Y, Liu W, Liu X, Long X, et al. Type I collagen reduces lipid accumulation during adipogenesis of preadipocytes 3T3-L1 via the YAP-mTOR-autophagy axis. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867:159181. [DOI] [PubMed]

45.

De Luca M, Mandala M, Rose G. Towards an understanding of the mechanoreciprocity process in adipocytes and its perturbation with aging. Mech Ageing Dev. 2021;197:111522. [DOI] [PubMed] [PMC]

46.

Varner VD, Nelson CM. Cellular and physical mechanisms of branching morphogenesis. Development. 2014;141:2750–9. [DOI] [PubMed] [PMC]

47.

Gjorevski N, Nelson CM. Endogenous patterns of mechanical stress are required for branching morphogenesis. Integr Biol. 2010;2:424–34. [DOI] [PubMed] [PMC]

48.

Northcott JM, Dean IS, Mouw JK, Weaver VM. Feeling stress: the mechanics of cancer progression and aggression. Front Cell Dev Biol. 2018;6:17. [DOI] [PubMed] [PMC]

49.

Yu H, Mouw JK, Weaver VM. Forcing form and function: biomechanical regulation of tumor evolution. Trends Cell Biol. 2011;21:47–56. [DOI] [PubMed] [PMC]

50.

Cha YJ, Jung WH, Koo JS. Site-specific expression of amine oxidases in breast cancer metastases. Tumour Biol. 2018;40:1010428318776822. [DOI] [PubMed]

51.

Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11:5120. [DOI] [PubMed] [PMC]

52.

Chan N, Willis A, Kornhauser N, Ward MM, Lee SB, Nackos E, et al. Influencing the tumor microenvironment: a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases. Clin Cancer Res. 2017;23:666–76. [DOI] [PubMed]

53.

Joo YN, Jin H, Eun SY, Park SW, Chang KC, Kim HJ. P2Y₂R activation by nucleotides released from the highly metastatic breast cancer cell contributes to pre-metastatic niche formation by mediating lysyl oxidase secretion, collagen crosslinking, and monocyte recruitment. Oncotarget. 2014;5:9322–34. [DOI] [PubMed] [PMC]

54.

Gunasinghe NPAD, Wells A, Thompson EW, Hugo HJ. Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev. 2012;31:469–78. [DOI] [PubMed]

55.

Leggett SE, Hruska AM, Guo M, Wong IY. The epithelial-mesenchymal transition and the cytoskeleton in bioengineered systems. Cell Commun Signal. 2021;19:32. [DOI] [PubMed] [PMC]

56.

Chronopoulos A, Tang A, Beglova E, Trackman PC, Roy S. High glucose increases lysyl oxidase expression and activity in retinal endothelial cells: mechanism for compromised extracellular matrix barrier function. Diabetes. 2010;59:3159–66. [DOI] [PubMed] [PMC]

57.

El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, et al. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci. 2012;109:17460–5. [DOI] [PubMed] [PMC]

58.

Carpéné C, Boulet N, Chaplin A, Mercader J. Past, present and future anti-obesity effects of flavin-containing and/or copper-containing amine oxidase inhibitors. Medicines (Basel). 2019;6:9. [DOI] [PubMed] [PMC]